Ftse Mib
33.639,08
-0,20%
DAX
18.254,42
0,51%
S&P 500
5.469,30
0,39%
NASDAQ
17.717,65
1,26%
Bitcoin
61.217,92
-0,96%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ FS Development Corporation II (FSII) FS Development Corporation II (FSII) Notizie

FSII

FS Development Corporati... (FSII)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:FSII
DataOraFonteTitoloSimboloCompagnia
05/06/202322:03Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:FSIIFS Development Corporation II
02/06/202322:14Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:FSIIFS Development Corporation II
05/05/202322:06Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:FSIIFS Development Corporation II
21/04/202322:28Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:FSIIFS Development Corporation II
20/04/202313:54Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:FSIIFS Development Corporation II
20/04/202313:50Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:FSIIFS Development Corporation II
14/03/202321:07Edgar (US Regulatory)Annual Report (10-k)NASDAQ:FSIIFS Development Corporation II
14/02/202323:07Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:FSIIFS Development Corporation II
23/01/202322:23Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:FSIIFS Development Corporation II
23/01/202312:03Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:FSIIFS Development Corporation II
18/01/202322:08Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:FSIIFS Development Corporation II
16/09/202222:05Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:FSIIFS Development Corporation II
26/04/202212:16Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:FSIIFS Development Corporation II
07/02/202222:02Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:FSIIFS Development Corporation II
28/01/202222:46Edgar (US Regulatory)Securities Registration Statement (s-1/a)NASDAQ:FSIIFS Development Corporation II
21/01/202222:29Edgar (US Regulatory)Securities Registration Statement (s-1)NASDAQ:FSIIFS Development Corporation II
30/12/202122:31Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:FSIIFS Development Corporation II
27/12/202113:00GlobeNewswire Inc.Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and Prevent COVID-19NASDAQ:FSIIFS Development Corporation II
23/12/202119:12Edgar (US Regulatory)Amended Securities Registration (section 12(b)) (8-a12b/a)NASDAQ:FSIIFS Development Corporation II
23/12/202117:16Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:FSIIFS Development Corporation II
21/12/202113:00Business WireFSII and Pardes Biosciences Move Towards Merger With the Goal of Tackling COVID-19 via an Oral Antiviral for Treatment and Prevention of SARS-CoV-2 InfectionsNASDAQ:FSIIFS Development Corporation II
01/12/202117:38Business WireFS Development Corp. II Announces Effectiveness of Registration Statement for Proposed Business Combination with Pardes Special Meeting Scheduled for December 23, 2021NASDAQ:FSIIFS Development Corporation II
23/11/202122:53Edgar (US Regulatory)Registration Statement for Securities to Be Issued in Business Combination Transactions (s-4/a)NASDAQ:FSIIFS Development Corporation II
23/11/202122:38Edgar (US Regulatory)Amended Quarterly Report (10-q/a)NASDAQ:FSIIFS Development Corporation II
26/08/202114:00GlobeNewswire Inc.Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat and Prevent SARS-CoV-2 InfectionsNASDAQ:FSIIFS Development Corporation II
05/08/202113:00GlobeNewswire Inc.Pardes Biosciences Appoints Deborah M. Autor, J.D. and Laura J. Hamill to Board of DirectorsNASDAQ:FSIIFS Development Corporation II
29/06/202112:00Business WirePardes Biosciences & FS Development Corp. II Announce Merger Agreement Creating Publicly Listed Biopharmaceutical Company Adv...NASDAQ:FSIIFS Development Corporation II
17/02/202103:36Business WireFS Development Corp. II, Sponsored by Foresite Capital, Announces Pricing of Upsized $175 Million Initial Public OfferingNASDAQ:FSIIFS Development Corporation II
11/10/201222:54Edgar (US Regulatory)Current report filing (8-K)NASDAQ:FSIIFS Development Corporation II
11/10/201222:49Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (SC 14D9/A)NASDAQ:FSIIFS Development Corporation II
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:FSII

La tua Cronologia

NEO
MWMN
Mackenzie Global Women's...
TSX
HED
BetaPro S&P TSX Capped E...
NASDAQ
TFM
NASDAQ
SHCR
Sharecare
LSE
52HX
Guin.ptnr 91/8%
BIT
P226V2
NLBNPIT226V2 20240625 90
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network